ClinicalTrials.gg
CompletedNCT05014971Updated Nov 16, 2026

Telehealth in Lewy Body Dementia

An interventional study of Tele-neurohub in Lewy Body Dementia With Behavioral Disturbance, Lewy Body Parkinson Disease and Lewy Body Disease, sponsored by University of Florida. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Florida · Not applicable, Interventional, and Health services research

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.

Enrollment
10th of 33
48 · median 35
Started
2022
the only one that year
No phase
25 of 41
5 open now
Registered
31st of 41
by date

Among the 41 studies in Parkinson Disease by University of Florida, this one is the 10th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2022, is one of 25 with no phase, and was the 31st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Parkinson Disease by University of Florida, or all of them as a file.
02

Study summary

Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.

Read the detailed description

The purpose of this study is to convert an in-person patient-centric interdisciplinary care model to a virtual platform using stakeholder engagement from individuals with LBD, their caregivers and healthcare providers. Subsequently researchers will conduct a prospective, randomized, controlled pilot study implementing the virtual stakeholder developed interdisciplinary care model (tele-neurohub) for 6 month and assess the implementation outcomes of feasibility, acceptability, and appropriateness of the tele-neurohub model. The research goal is to establish and iteratively improve a virtual interdisciplinary model of care allowing patients with LBD and their caregivers to access sub-specialty care from their home.

03

Conditions studied

  • Lewy Body Dementia With Behavioral Disturbance
  • Lewy Body Parkinson Disease
  • Lewy Body Disease
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Participant with Lewy Body Dementia (LBD) Inclusion Criteria:

  • LBD diagnosis by a dementia or movement disorders specialist
  • Clinician-determined mild-moderate dementia severity
  • Internet access with a Zoom-compatible device
  • Caregiver who resides in the patient's home and is willing to participate
  • Fluency in English
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tele-neurohub

    This group will receive the tele-neurohub intervention which includes telemedicine appointments with the neurologist, speech therapist, social worker, and nutritionist at baseline, 3 months and 6 months, and PT and OT every 2 weeks for maintenance neuro-rehabilitation.

    Behavioral: Tele-neurohub

  • Active comparator
    Usual care group

    Receive usual care but will have study visit assessments at baseline and 6 months.

    Behavioral: Tele-neurohub

Interventions

  • BehavioralTele-neurohub

    Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.

06

What researchers measure

Primary outcomes

  1. Number of completed tele-health visits

    Feasibility will be determined by completion of at least 75% telehealth visits by the intervention cohort

    Time frame: 6 months

Secondary outcomes

  1. Satisfaction assessed by Patient Assessment of Communication of Telehealth questionnaire.

    Acceptability will be determined by at least 80% of dyads reporting being "satisfied" or "highly satisfied" on the Patient Assessment of Communication of Telehealth questionnaire.

    Time frame: 6 months

  2. Appropriateness assessed by Intervention Appropriateness Measure

    Appropriateness will be determined by the Intervention Appropriateness Measure, higher scores indicate greater appropriateness

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Nov 2026, 56 months.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 56 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Aug 20, 2021
StartActual
Feb 28, 2022
Primary completionActual
Nov 4, 2026was Oct 2026
CompletionActual
Nov 4, 2026was Oct 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Oct 31, 2026→Nov 4, 2026 (actual)
Nov 16, 2026
Study completion
Oct 31, 2026→Nov 4, 2026 (actual)
Nov 16, 2026
Enrollment
106 (estimated)→48 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Oct 31, 2026→Nov 4, 2026 (now actual)
    Study completion Oct 31, 2026→Nov 4, 2026 (now actual)
    Enrollment 106 (estimated)→48 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05014971
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Feb 28, 2022
Primary completion
Nov 4, 2026
Completion
Nov 4, 2026
Last update
Nov 16, 2026

Study contacts

Bhavana Patel, DO
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion